ARTICLE | Clinical News
NiCord regulatory update
October 24, 2016 7:00 AM UTC
FDA granted breakthrough therapy designation to NiCord from Gamida Cell as a graft modality for bone marrow transplantation in patients with high-risk hematological malignancies. NiCord comprises umbi...